Melanie McCauley

Aug 14, 2024 | thelancet.com | Kayvon Modjarrad |Paul Scott |Melanie McCauley

Background Recent outbreaks between 2015–17 and production delays have led to a yellow fever vaccine shortage. Therefore, there is an urgent need for new yellow fever vaccines with improved production scalability. A next-generation live-attenuated yellow fever vaccine candidate (vYF), produced in a Vero cell line has shown similar immunogenicity to licensed yellow fever vaccines in preclinical studies.

Jun 5, 2024 | biorxiv.org | Annie Elong Ngono |Sabita Prajapati |Melanie McCauley |Julia Timis

AbstractDengue virus (DENV) is a mosquito borne flavivirus that poses a threat to nearly 50% of the global population. DENV has been endemic in Nepal since 2006; however, little is known about how DENV is evolving or the prevalence of anti DENV immunity within the Nepalese population. To begin to address these gaps, we performed a serologic and genetic study of 49 patients from across Nepal who presented at central hospitals during the 2017 dengue season with suspected DENV infection.